News | January 16, 2025
Briefs: Morepen Laboratories, Glenmark Life Sciences, Gland Pharma and Shalby
Morepen Laboratories approves hiving off of medical devices business
Morepen Laboratories approves hiving off of medical devices business
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
According to IQVIA, the European market for Buprenorphine-based opioid dependency treatments in 2023 surpassed USD 355 million annually
The certification marks a new chapter in Windlas Biotech’s growth trajectory,
The site’s GMP Certification has been successfully renewed
Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
The inspection, which is a routine part of the FDA's regulatory oversight, evaluates compliance with Good Manufacturing Practices and other regulatory requirements.
NutrifyGenie AI, a leading AI-driven platform, was integral in designing scientifically differentiated formulations for a multinational client
The biosimilar Ustekinumab has been developed and manufactured by the company
He has 29+ years’ comprehensive experience in world-class Formulations and API (for US and EU requirements) mainly related to injectables
Subscribe To Our Newsletter & Stay Updated
